Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
Grant
Overview
Affiliation
Overview
Date/time Interval
November 4, 2016 - November 3, 2024
Awarded By
CHILDREN'S HOSPITAL (PHILADELPHIA)
Total Award Amount
18500.00
Direct Costs
14683.00
Sponsor Award Id
Affiliation
Contributor
Ana Galtarossa Xavier
Investigator
Jeanine Dumas
Investigator
Julie Wolfson-Stockman M.D.
Investigator
Matthew Kutny M.D.
Principal Investigator